CatalYm
The company develops visugromab, a monoclonal antibody designed to neutralize GDF-15 to reverse immune resistance mechanisms in solid tumors. By reenabling immune cell activation and tumor infiltration, the therapy aims to reset responses to checkpoint inhibition. The pipeline also includes treatments targeting cancer cachexia, with clinical trials currently in Phase 2/3 development.
Biotechnology
Oncology
Immunotherapy
Funding summary
- Total raised
- €100.0M
- Funding rounds
- 2
Investors in CatalYm
Investors on record for CatalYm. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like CatalYm?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors